Join the club for FREE to access the whole archive and other member benefits.

Lloyd Klickstein

Chief Innovation Officer at Adicet Bio, Inc.

Dr. Klickstein has served as Adicet’s Chief Innovation Officer since its merger with resTORbio in September 2020, formerly holding the role of Chief Scientific Officer of resTORbio. Prior to joining resTORbio, Dr. Klickstein was Head of Translational Medicine for the New Indication Discovery Unit (NIDU) and the Exploratory Disease Area (DAx) at Novartis Institutes for Biomedical Research. Under his decade of leadership, NIDU & DAx teams carried multiple projects forward from target identification through clinical proof-of-concept in novel areas of drug development including liver disease, hearing loss and aging, among others. Prior to his 13 years at Novartis, Dr. Klickstein was an academic physician-scientist at Brigham & Women’s Hospital (BWH) in Boston, where he directed an NIH-funded basic research laboratory and maintained an active clinical practice in the Arthritis Center. Dr. Klickstein received his B.S. degree from Tufts University, his M.D. and Ph.D. degrees from Harvard University, completed post-graduate clinical training in Internal Medicine, Rheumatology & Immunology at BWH and a post-doctoral research fellowship at the Center for Blood Research in Boston.

Visit website:


See also: Company Adicet Bio - Biotechnology company

Details last updated 17-Feb-2021

Lloyd Klickstein News

Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year